21 April 2026 Patients with a specific bowel cancer who were given short-course immunotherapy before surgery, instead of post-op chemotherapy, remained cancer-free after nearly three years of follow-up, according to new results from the NEOPRISM-CRC trial led by UCL and UCLH. Read: The Telegraph (£) More: Daily Mail , The Independent , The Sun , Express , UCL News